SCHEMBL6711213

SCHEMBL6711213

O=C(Nc1nc2ccc(F)cc2s1)C(=O)c1c2n(c3ccccc13)CCNCC2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.52
HTR2C P28335 3/20 0.52
LRRK2 Q5S007 2/20 0.46
CSNK2A2 P19784 1/20 0.45
CSNK2B P67870 1/20 0.45
CSNK2A1 P68400 1/20 0.45
CSNK2A3 Q8NEV1 1/20 0.45
PDPK1 O15530 1/20 0.44
DYRK1A Q13627 1/20 0.44
MAPT P10636 3/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
KMT2A Q03164 2/20 0.43
HTT P42858 2/20 0.43
POLB P06746 1/20 0.43
PKM P14618 1/20 0.43
AGTR1 P30556 1/20 0.43
OPRK1 P41145 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6715283 0.90 HTR2A (0.52) HTR2AHTR2CLRRK2DYRK1AMAPT
SCHEMBL6718786 0.90 HTR2A (0.52) HTR2AHTR2CLRRK2CSNK2A2CSNK2B
SCHEMBL6711186 0.89 HTR2A (0.57) HTR2AHTR2CLRRK2CSNK2A2CSNK2B
SCHEMBL6718997 0.89 HTR2A (0.51) HTR2AHTR2CLRRK2CSNK2A2CSNK2B
SCHEMBL6713935 0.88 HTR2A (0.49) HTR2AHTR2CCSNK2A2CSNK2BCSNK2A1
SCHEMBL6715286 0.87 HTR2A (0.51) HTR2AHTR2CMAPTNPC1RAB9A
SCHEMBL6718993 0.87 HTR2A (0.49) HTR2AHTR2CCSNK2A2CSNK2BCSNK2A1
SCHEMBL6715514 0.87 CSNK2A2 (0.49) HTR2AHTR2CCSNK2A2CSNK2BCSNK2A1
SCHEMBL6718323 0.87 HTR2A (0.52) HTR2AHTR2CCSNK2A2CSNK2BCSNK2A1
SCHEMBL6713532 0.87 HTR2A (0.52) HTR2AHTR2CMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6734301-B2 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-05-11 US claimed
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds ENNIS MICHAEL DALTON (US) 2004-10-21 US disclosed
US-6734301-B2 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-05-11 US disclosed
EP-1328525-A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-A]INDOLE COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2003-07-23 EP disclosed
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds PHARMACIA & UPJOHN COMPANY 2002-01-03 US disclosed
WO-2001072752-A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-a]INDOLE COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HTR1D, HTR1A, HTR1E HTR2A 18/4885HTR2C 7/4885LRRK2 2497/4885
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HCRTR2, NR2C2, RCOR3 HTR2A 1403/4885HTR2C 553/4885LRRK2 1844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.